Title:
INTERFERON-BETA POLYNUCLEOTIDE THERAPY FOR AUTOIMMUNE AND INFLAMMATORY DISEASES
Document Type and Number:
WIPO Patent Application WO2002072019
Kind Code:
A3
Abstract:
The present invention relates to methods of treating an autoimmune disease or an inflammatory condition, and in particular multiple sclerosis, in a mammal comprising administering a therapeutically effective amount of a non-infectious, non-integrating polynucleotide construct encoding a beta interferon or an active fragment or variant thereof, wherein said construct is not associated with transfection-facilitating viral particles, liposomal formulation, or charged lipids.
More Like This:
Inventors:
PARKER SUEZANNE E (US)
HORTON HOLLY M (US)
HORTON HOLLY M (US)
Application Number:
PCT/US2002/007393
Publication Date:
February 20, 2003
Filing Date:
March 13, 2002
Export Citation:
Assignee:
VICAL INC (US)
PARKER SUEZANNE E (US)
HORTON HOLLY M (US)
PARKER SUEZANNE E (US)
HORTON HOLLY M (US)
International Classes:
A61K38/21; A61P21/04; A61P29/00; A61P37/00; C12N15/22; A61K48/00; (IPC1-7): A61K48/00
Domestic Patent References:
| WO2001015736A2 | 2001-03-08 |
Foreign References:
| US5545723A | 1996-08-13 |
Other References:
CROXFORD ET AL.: "Cytokine gene therapy in experimental allergic encaphalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system", J. IMMUNOL., vol. 160, 1998, pages 5181 - 5187, XP002194905
TRIANTAPHYLLOPOULOS ET AL.: "Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12 and tumor necrosis factor alpha production by interferon-beta gene therapy", ARTHRITIS & RHEUMATISM, vol. 42, no. 1, January 1999 (1999-01-01), pages 90 - 99, XP002954377
TAO ET AL.: "Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver", MOLECULAR THERAPY, vol. 3, no. 1, January 2001 (2001-01-01), pages 28 - 35, XP002954378
ECK ET AL.: "Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): A phase I trial", HUMAN GENE THERAPY, vol. 12, 1 January 2001 (2001-01-01), pages 97 - 113, XP002954379
TADA ET AL.: "Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases", J. CLIN. INVEST., vol. 108, no. 1, July 2001 (2001-07-01), pages 83 - 95, XP002954380
QIN ET AL.: "Human and mouse IFN-beta gene therapy exhibits different anti-timor mechanisms in mouse models", MOLECULAR THERAPY, vol. 4, no. 4, October 2001 (2001-10-01), pages 356 - 364, XP002954381
TRIANTAPHYLLOPOULOS ET AL.: "Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12 and tumor necrosis factor alpha production by interferon-beta gene therapy", ARTHRITIS & RHEUMATISM, vol. 42, no. 1, January 1999 (1999-01-01), pages 90 - 99, XP002954377
TAO ET AL.: "Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver", MOLECULAR THERAPY, vol. 3, no. 1, January 2001 (2001-01-01), pages 28 - 35, XP002954378
ECK ET AL.: "Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): A phase I trial", HUMAN GENE THERAPY, vol. 12, 1 January 2001 (2001-01-01), pages 97 - 113, XP002954379
TADA ET AL.: "Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases", J. CLIN. INVEST., vol. 108, no. 1, July 2001 (2001-07-01), pages 83 - 95, XP002954380
QIN ET AL.: "Human and mouse IFN-beta gene therapy exhibits different anti-timor mechanisms in mouse models", MOLECULAR THERAPY, vol. 4, no. 4, October 2001 (2001-10-01), pages 356 - 364, XP002954381
Download PDF:
Previous Patent: A CREAM-T0-POWDER DERMATOLOGICAL COMPOSITION
Next Patent: NOVEL ANTI-ADHESIVE COMPOUNDS AND USES THEREOF
Next Patent: NOVEL ANTI-ADHESIVE COMPOUNDS AND USES THEREOF